Boston Scientific Taxus PMA, Visx CustomVue Approval Spark Q2 Index Gains
This article was originally published in The Gray Sheet
Executive Summary
Anticipation of Boston Scientific's Taxus drug-eluting stent premarket approval submission to FDA helped lift the company's stock price by 50% in the second quarter, signaling investor confidence that the device successfully meets primary clinical endpoints